Detalhe da pesquisa
1.
Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?
Oncologist
; 24(11): e1148-e1155, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31036771
2.
Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy.
Future Oncol
; 15(22): 2645-2656, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31298573
3.
NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma.
Cancer
; 124(3): 537-545, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29044496
4.
Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma.
Int J Mol Sci
; 18(11)2017 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29099775
5.
A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis.
Prostate Cancer Prostatic Dis
; 2024 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38341460
6.
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.
Nat Commun
; 15(1): 1430, 2024 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38365756
7.
Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.
BJU Int
; 111(7): 1046-53, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23551810
8.
Patient- and Provider-Level Factors Associated With Telehealth Utilization Across a Multisite, Multiregional Cancer Practice From 2019 to 2021.
JCO Oncol Pract
; 19(9): 750-758, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37335959
9.
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses.
Front Immunol
; 14: 1279387, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38022659
10.
Personalized therapy for metastatic melanoma: could timing be everything?
Future Oncol
; 8(11): 1401-6, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23148614
11.
NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy.
Cancer Immunol Res
; 10(2): 162-181, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34911739
12.
Cancer Mortality Rates Increasing vs Cardiovascular Disease Mortality Decreasing in the World: Future Implications.
Mayo Clin Proc Innov Qual Outcomes
; 5(3): 645-653, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34195556
13.
Peptide vaccine with glucopyranosyl lipid A-stable oil-in-water emulsion for patients with resected melanoma.
Immunotherapy
; 12(13): 983-995, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32752904
14.
Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients.
Melanoma Res
; 30(4): 364-375, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32404734
15.
Sex-Based Differences in Melanoma Survival in a Contemporary Patient Cohort.
J Womens Health (Larchmt)
; 29(9): 1160-1167, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32105561
16.
Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles.
J Immunother Cancer
; 8(2)2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32817395
17.
ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance.
Oncoimmunology
; 9(1): 1744980, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32363112
18.
Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations.
PLoS One
; 15(3): e0230306, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32196516
19.
Immune Checkpoint Inhibitor Toxicities.
Mayo Clin Proc
; 94(7): 1321-1329, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31272574
20.
Paradox-driven adventures in the development of cancer immunology and immunotherapy.
Genes Dis
; 6(3): 224-231, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32042862